Activation of H-ras61L-specific signaling pathways does not require posttranslational processing of H-ras

被引:5
作者
Hart, KC
Robertson, SC
Donoghue, DJ [1 ]
机构
[1] Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
关键词
H-ras; MAPK cascade; posttranslational modifications; protein localization; signal transduction;
D O I
10.1006/excr.2000.4874
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously demonstrated that H-ras(61L) retained transforming activity when lacking C-terminal lipid modifications, provided that plasma membrane localization was restored by an N-terminal transmembrane domain. Since several ras-activated pathways contribute to the transformed phenotype, we utilized a novel set of transmembrane domain-anchored H-ras derivatives to examine if lipids are required for activation of any specific signaling pathways. We demonstrate here that H-ras(61L)-induced activation of the Rafl MEK/MAPK pathway, including recruitment of Raf to the plasma membrane and activation of Raf and MAPK, does not require C-terminal processing of H-ras(61L). Biochemical fractionation experiments confirm the localization of TM-ras derivatives to the plasma membrane, as well as the ras-mediated recruitment of c-Raf-1. Changes in the actin cytoskeleton, controlled by H-ras(61L)-mediated activation of the Rac/ Rho pathway, as well as PI 3-kinase activation, can also occur in the absence of C-terminal lipid modifications. Finally, downstream events, such as the induction of the immediate-early gene c-fos or neurite outgrowth in PC12 cells, are stimulated by the expression of plasma membrane-anchored, nonlipidated H-ras(61L) These results demonstrate that H-ras can be functionally targeted to the plasma membrane using a transmembrane domain sequence and that several signal transduction pathways downstream of H-ras can be activated without the presence of normal lipid modifications. (C) 2000 Academic Press.
引用
收藏
页码:89 / 100
页数:12
相关论文
共 71 条
  • [31] KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461
  • [32] KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443
  • [33] KIKUCHI A, 1994, J BIOL CHEM, V269, P20054
  • [34] THE EFFECT OF POSTTRANSLATIONAL MODIFICATIONS ON THE INTERACTION OF RAS2 WITH ADENYLYL CYCLASE
    KURODA, Y
    SUZUKI, N
    KATAOKA, T
    [J]. SCIENCE, 1993, 259 (5095) : 683 - 686
  • [35] RAF-1 ACTIVATES MAP KINASE-KINASE
    KYRIAKIS, JM
    APP, H
    ZHANG, XF
    BANERJEE, P
    BRAUTIGAN, DL
    RAPP, UR
    AVRUCH, J
    [J]. NATURE, 1992, 358 (6385) : 417 - 421
  • [36] LACAL PM, 1988, ONCOGENE, V2, P533
  • [37] Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription
    Lebowitz, PF
    Du, W
    Prendergast, GC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (26) : 16093 - 16095
  • [38] REQUIREMENT FOR RAS IN RAF ACTIVATION IS OVERCOME BY TARGETING RAF TO THE PLASMA-MEMBRANE
    LEEVERS, SJ
    PATERSON, HF
    MARSHALL, CJ
    [J]. NATURE, 1994, 369 (6479) : 411 - 414
  • [39] GROWTH-FACTORS INDUCE NUCLEAR TRANSLOCATION OF MAP KINASES (P42(MAPK) AND P44(MAPK)) BUT NOT OF THEIR ACTIVATOR MAP KINASE KINASE (P45(MAPKK)) IN FIBROBLASTS
    LENORMAND, P
    SARDET, C
    PAGES, G
    LALLEMAIN, G
    BRUNET, A
    POUYSSEGUR, J
    [J]. JOURNAL OF CELL BIOLOGY, 1993, 122 (05) : 1079 - 1088
  • [40] Ras farnesyltransferase: A new therapeutic target
    Leonard, DM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (19) : 2971 - 2990